You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

209 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
exemestane,
palbociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Document
Nov 2018
Document
Nov 2018
Guidelines and Advice
Status: In-Review
ID: 7-14
Version: 3
Dec 2018
Last updated: April 30, 2019 The following information identifies errors and corrections in the Ontario Cancer Statistics 2018 report and supporting...
Mar 2019
Document
Apr 2019
Guidelines and Advice
Status: Current
Mar 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
venetoclax,
riTUXimab,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Document
May 2019
Document
May 2019
Document
May 2019

Pages